CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从 COVID-19 大流行中汲取的经验教训：造血细胞移植和细胞治疗受者感染 SARS-CoV-2 后的结局
英文原题：Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
查看英文原题
Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们在一项单中心研究中调查了2019冠状病毒病（COVID）在造血细胞移植（HCT）或CAR-T 细胞治疗接受者中的结局，该研究纳入了所有（n = 261）HCT/CAR-T 接受者（异基因HCT 49%，自体HCT 40%，CAR-T 11%）。中位年龄为60（22-80）岁。COVID严重程度为轻度（74%）、中度（11%）和重度/危重（16%），死亡率为7%，中位感染持续时间为5.7周。COVID重症或死亡的显著预测因素包括合并感染（HR 14.9，95% CI 2.2-5.6）和免疫抑制治疗（OR 4.8，95% CI 1.2-3.4）。HCT/CAR-T 接受者因COVID死亡的风险更高，需要警惕性干预。
展开英文摘要原文
We investigated the outcomes after Coronavirus disease 2019 (COVID) in hematopoietic cell transplant (HCT) or chimeric antigen receptor-T cell (CART) therapy recipients in a single-centre study including all ( n = 261)HCT/CART recipients (allogeneic-HCT 49%, autologous-HCT 40%, CART 11%). The median age was 60 (22-80) years.
COVID severity was mild (74%), moderate (11%), and severe/critical (16%) with a mortality rate of 7% and a median duration of infection of 5. 7 weeks. Significant predictors of COVID severe disease or mortality included concurrent infection (HR 14. 9, 95% CI 2. 2-5. 6) and immunosuppressive therapy (OR 4. 8, 95% CI 1. 2-3. 4). HCT/CART recipients have a higher risk of mortality with COVID and warrant vigilant interventions.
论文信息
- 作者
- Al-Ramahi JS、Shahzad M、Li K、DeJarnette S、Chaudhary SG、Lutfi F、Ahmed N、Balusu R
- 单位
- Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.United States
- 文献类型
- 非美国政府资助研究
- 期刊
- Leukemia & lymphoma2023 Dec
- 原文标识
- PubMed 37574842 · DOI 10.1080/10428194.2023.2243355